PBAC rec­om­mends biosim­i­lar de­fault

Pharmacy Daily - - NEWS -

THE Phar­ma­ceu­ti­cal Ben­e­fits Ad­vi­sory Com­mit­tee says it does not have “any con­cerns about en­cour­ag­ing pre­scrib­ing of a biosim­i­lar brand rather than the ref­er­ence bi­o­log­i­cal agent brand”.

Ac­cord­ing to the out­comes from the Aug 2017 PBAC meet­ing, the com­mit­tee was asked to re­view a re­quest for a change to the PBS Sched­ule and pre­scrib­ing soft­ware to give preference to a biosim­i­lar brand of etan­er­cept for pa­tients who hadn’t been pre­vi­ously treated with the med­i­ca­tion.

The PBAC noted that while such a move was a mat­ter for the gov­ern­ment, it was happy to en­cour­age pre­scrib­ing of the biosim­i­lar brand, in­clud­ing through notes in the Sched­ule and changes to pre­scrib­ing soft­ware.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.